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Abstract
Background: To evaluate the therapeutic strategies commonly employed in the clinic for the management of
brain metastases (BMs) and to correlate disease outcome with type of treatment and therapeutic resources
available at the treating center.
Methods: Four Cancer centres participated to the survey. Data were collected through a questionnaire filled in by
one physician for each centre.
Results: Clinical data regarding 290 cancer patients with BMs from solid tumors were collected. Median age was
59 and 59% of patients had ≤ 3 brain metastases. A local approach (surgery and stereotactic radiosurgery) was
adopted in 31% of patients. The local approach demonstrated to be superior in terms of survival compared to the
regional/systemic approach (whole brain radiotherapy and chemotherapy, p = <.0001 for survival at 2 years). In the
multivariate analysis local treatment was an independent prognostic factor for survival. When patients were divided
into 2 groups whether they were treated in centers where local approaches were available or not (group A vs
group B respectively, 58% of patients with ≤ 3 BMs in both cohorts), more patients in group A received local
strategies although no difference in time to brain progression at 1 year was observed between the two groups of
patients.
Conclusions: In clinical practice, local strategies should be integrated in the management of brain metastases.
Proper selection of patients who are candidate to local treatments is of crucial importance.
Background
Intracranial metastases represent the most common
brain tumors, occurring in 25-50% of all cancer patients
(based on clinical studies, hospital records and autopsy
series) [1,2]. Given the high rate of cancer patients who
will metastasize to the brain during the course of their
disease, brain metastases (BMs) constitute a major
health care problem. As new and more effective thera-
pies for treating primary tumors lengthen patient
survival and the availability of enhanced cerebral
imaging techniques favors the detection of small and
asymptomatic brain lesions, the incidence of BMs is
expected to increase.
In adults, lung cancer is the main cause of BMs
(50-60%), followed by breast cancer (15-20%) and mela-
noma (5-10%) respectively, while tumors of the gastroin-
testinal tract and renal cell carcinomas are less common
origins of metastases to the brain [2]. In fewer cases,
intracranial involvement is the first and unique manifes-
tation of cancer as for patients with adenocarcinoma of
unknown primary site [3]. In cancer patients who will
develop BMs median time to brain recurrence is about
12 months [4] and, without treatment, median survival
from detection of BMs rarely exceeds 1 month [5].
Neverthless, survival is influenced by several prognostic
factors: high Karnofsky Performance Status (KPS),
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younger age (< 65 years), good control of primary tumor
and absence of extracranial disease are among factors
predicting for better survival [6,7]. Other positive prog-
nostic factors include presence of a brain metastasis,
favorable tumor histology, response to steroid treatment
and no impairment of neurocognitive functions [7,8].
Using recursive partitioning analysis (RPA) derived from
a database of several Radiation Therapy Oncology
Group (RTOG) trials, Gaspar et al. identified three prog-
nostic categories of patients with a significant inter-
group variability of survival (from 7.1 months for RPA
class I to 2.3 months for class III patients) [6].
Over the past few decades, whole brain radiotherapy
(WBRT) has been considered the standard treatment for
brain metastases [9]. More recently, stereotactic radiosur-
gery (SRS), namely the delivery of a single, high-dose frac-
tion of external radiation to a target lesion in the brain,
has emerged as a promising therapeutic option for these
patients. Surgery is another important treatment modality
for BMs, although current evidence suggests that it should
be reserved to selected patients with single brain metasta-
sis and favorable prognostic factors [10]. Regarding che-
motherapy, its poor activity in cerebral metastases can
only be partially attributed to the blood-brain barrier
(BBB), that limits the penetration of some chemothera-
peutic agents into thecentral nervous system (CNS). How-
ever, the mechanisms responsible for molecular
transportation across the BBB have been only partially elu-
cidated. Moreover, the tumor-specific enhancing proper-
ties of agents used in Computed Tomography (CT) and
Magnetic Resonance Imaging (MRI) also suggest that BBB
might be partially disrupted in patients with brain metas-
tases. As a result, intracranial responses are observed in
chemosensitive tumors [11] and new chemotherapeutic
and biologic agents show in the CNS an activity similar to
that exhibited at extracranial sites [12,13].
In the context of a multidisciplinary approach involving
different specialists, namely oncologists, radiotherapists
and neurologic surgeons, thoughtful appropriate observa-
tional studies are helpful to guide clinical management.
On behalf of the Neuro-Oncology Group Consortium for
Outcome Research, we carried out a survey on cancer
patients treated for BMs derived from solid tumors. Four
different Italian institutions participated to the survey.
Our aims were a) to evaluate in an unselected population
of patients the strategies commonly employed for the
management of BMs b) to correlate the type of treatment
with clinical outcome c) to define whether the unavail-
ability of local approaches (neurosurgery and SRS) at the
referring centers would impact on disease outcome.
Methods
Cancer patients with BMs referring to four different Ita-
lian institution ("Regina Elena” National Cancer Institute
in Rome, “I.N.I.” Hospital in Grottaferrata, “Umberto I”
Hospital in Frosinone and “Belcolle” Hospital in
Viterbo) were recruited for the survey. To be included,
patients had to have received at least one treatment for
brain metastases. The resources available at each institu-
tion are described in Table 1. Local treatments (neuro-
surgery and SRS) were available only in one center,
while WBRT and chemotherapy were available in two
and three centers respectively.
For each patient the following clinical data were
obtained through a questionnaire filled in by one physi-
cian per center: age, sex, primary tumor, date of initial
diagnosis of primary cancer, date of radiographic diag-
nosis of BMs, number and location of BMs, neurologic
symptoms, presence/absence of extracranial disease, up-
front treatment for BMs, date of progression of BMs,
type of second treatment for BMs, death of the patient.
Data were recorded in a central data base system at the
Regina Elena National Cancer Institute. For the aims of
this study:
Chemotherapy: refers to the administration of any
cytotoxic drugs currently approved for use in the meta-
static setting of each specific tumor.
SRS: indicates any single high fraction dose of focal
radiotherapy delivered from a linear accelerator
(LINAC) or g-rays from Cobalt-60 sources in a gamma
knife.
Surgical resection: refers to complete removal of the
tumor by any macroscopic excision procedure.
Whole brain radiotherapy: refers to entire brain radio-
therapy to a total dose of 30 Gy.
Statistical analysis
The standard summary statistics was used for both con-
tinuous and discrete variables. The objective response
rate was reported with its 95% Confidence Interval (CI).
Time to brain recurrence was the time in months
between the diagnosis of primary cancer and the radio-
graphic detection of brain metastases. Time to brain
progression and overall survival were calculated accord-
ing to the Kaplan-Meier method from the date of first
treatment for BMs to the date of brain progression or
death, respectively [14]. If a patient had no progression
or death, the time to progression or the survival was
Table 1 Availability of resources at each Institution
Centre Neurosurgery SRS WBRT Chemotherapy Patients Cohort
1a Yes Yes Yes Yes 235 A
2b No No Yes Yes 28 B
3c No No No Yes 16
4d No No No Yes 11
aRegina Elena National Cancer Institute (Rome); bBelcolle Hospital (Viterbo); cI.
N.I. Hospital (Grottaferrata-Rome); dUmberto I Hospital (Frosinone).
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censored at the time of the last visit. The differences in
survival were compared by long rank test.
The Hazard risk and the confidence limits were esti-
mated for each variable using the Cox univariate model
and adopting the most suitable prognostic category as
referent group. A multivariate Cox proportional hazard
model was also adopted using stepwise regression (for-
ward selection) with predictive variables which were sig-
nificant in the univariate analyses. Enter limit and
remove limit were p = 0.10 and p = 0.15, respectively.
The SPSS (11.0) statistical program was used for
analysis.
Results
From October 2004 to April 2007 clinical data from 290
patients with BMs from different solid tumors were col-
lected. Characteristics of patients are reported in Table 2.
The most represented BMs were those from non-small
cell lung cancer (NSCLC) (44%), followed in decreasing
order of frequency by breast cancer (29.5%), colorectal
cancer (8.5%) and melanoma (6%). Nearly all patients
had a KPS ≥ 70 and presented with extra-cranial disease.
Forty-one percent of patients had more than 3 brain
metastases.
Tumor-specific time to brain recurrence was as fol-
lows: 46 months (range 2-207) for breast cancer,
42 months (range 3-75) for colorectal cancer, 22 months
(range 1-153) for melanoma and 9 months (range 1-105)
for NSCLC. Overall, median time to brain recurrence
was 25 months (range 1-274).
All 290 patients received at least one up-front treat-
ment for BMs, while only half of them (n = 145)
received also a second-line treatment (Table 3). Whole
brain radiotherapy (WBRT) was the first chosen option
in the majority of cases (n = 136, 47%), followed by che-
motherapy (n = 66, 23%), surgery (n = 60, 21%) and
SRS (n = 28, 10%) respectively. Among the 145 patients
receiving a second-line treatment for BMs, chemother-
apy and WBRT were the most used approach (51% and
36.5% respectively).
Among patients who underwent a local approach as
first treatment, namely surgery or SRS, those with ≤ 3
brain lesions were 92% (n = 55/60) and 100% (n = 28/
28) respectively. Among patients receiving WBRT and
chemotherapy as up-front therapy, patients with > 3
BMs were 62% (n = 84/136) and 41% (n = 27/66).
Only patients with BMs from the four most frequent
primary cancers (NSCLC, breast, colorectal cancer, and
melanoma, n = 253) were considered for analyses of
time to brain progression and survival. At a median fol-
low-up of 25 months (range 1-104) from detection of
BMs, time to brain progression was 26 months (C.I.
95%: 23-29) and survival was 13 months (C.I. 95%: 10-
16). At 1, 2 and 3 years, 52%, 26% and 12% of patients
were still alive respectively.
Median time to brain tumor progression was
11 months for either breast cancer (C.I. 95%: 7-14) and
melanoma (C.I. 95%: 6-17), 9 months for NSCLC (C.I.
95%: 7-10) and 5 months (C.I. 95%: 2-8) for colorectal
cancer (P = .03). The corresponding 1- and 2-year survi-
val rate were 58 % and 36% for breast cancer (median
survival 16 months, C.I. 95%: 11-20), 51% and 20% for
NSCLC (median survival 12 months, C.I.95%: 9-16), 40%
and 18% for melanoma (median survival 10 months, C.I.
Table 2 Demographic
Total patients 290
Age - years
Median (range) 59 (20-88)
< 65 years 200 (69%)
≥ 65 years 90 (31%)
Gender (%)
Male 133 (46)
Female 157 (54)
Neurocognitive impairment (%)
Yes 160 (55)
No 130 (54)
Primary tumor (%)
Lung (NSCLC) 126 (44)
Breast 85 (29.5)
Colon-rectum 24 (8.5)
Melanoma 18 (6)
Others 37 (12)
RPA-RTOG classes (%)
I 80 (27.5)
II 148 (51)
III 62 (21.5)
Number of BMs (%)
≤ 3 180 (59)
>3 120 (41)
Location of BMs (%)
Supratentorial 144 (50)
Subtentorial 44 (15)
Supra/Subtentorial 102 (35)
Extra-cranial disease (%)
Yes 278 (96)
No 12 (4)
Table 3 Treatments for Brain Metastases
First-line treatment
(n = 290 pts)
Second-line treatment
(n = 145 pts)
Surgery 60 (20.5%) 10 (7%)
Radiosurgery 28 (9.5%) 8 (5.5%)
WBRT 136 (7%) 53 (36.5%)
Chemotherapy 66 (23%) 74 (51%)
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95%:9-14) and 18% and 9% for colorectal cancer (med-
ian survival 6 months, C.I. 95%:1-12) respectively
(P = .01) (Figure 1).
Local approaches (surgery or SRS) demonstrated to be
superior in terms of time to BM progression and survi-
val compared to either WBRT and chemotherapy
(P = .02 and P = .0001 respectively) (Table 4; Figure 2).
Multivariate analysis found that primary tumor, neurolo-
gic symptoms at diagnosis of brain involvement, number
of BMs, and type of treatment were independent prog-
nostic factors for survival (Table 5).
To assess whether the availability of resources for
local approach would impact on disease outcome of
patients with BMs, we analyzed the up-front strategy for
BMs on the basis of the treatment received at each insti-
tution with respect to the number of brain lesions (≤ 3
vs > 3). Group A included 235 patients referring to a
comprehensive cancer center where resources for either
local (surgery and SRS) and regional/systemic (WBRT
and chemotherapy) approaches were available. Group B
included 55 patients referring to 3 different institutions
where only regional/systemic approaches were available
(WBRT in one center, chemotherapy in all centers)
(Table 1). Patients with ≤ 3 brain lesions were 58% in
both cohorts (n = 137/235 for group A and n = 32/55
for group B). In subpopulation of patients with ≤ 3
BMs, local treatment was delivered in 54% of cases for
group A (75 out of 137 patients) but in only 18% for
group B (6 out of 32 patients). No difference was found
in terms of time to brain progression at 1 year between
group A and B (74.2% vs 71.6% respectively, P = .89).
Discussion
In this survey, we aimed at assessing the therapeutic
strategies currently adopted in the clinic for unselected
patients with BMs from solid tumors treated at four Ita-
lian cancer institutions. The cure algorithm for patients
with BMs is extremely variable and depends on several
factors such as primary histology and other clinical
characteristics of patients. Moreover, though a multidis-
ciplinary strategy is needed when approaching such
complex patients, the lack of technical resources may
influence the therapeutic decision of the treating physi-
cian. In fact, in clinical practice, the treatment of BMs is
often planned on the basis of the resources available at
each treating center.
The incidence of BMs reported in our series of
patients for each tumor was similar to that reported in
other studies [2]. In our analysis, breast cancer was the
tumor with the longest time to brain recurrence
(46 months), probably reflecting the advantages of an
early diagnosis and the availability of effective treat-
ments. In fact, anthracycline- and taxanes-including
regimens as well as new hormonal and biologic agents
have significantly increased disease-free and overall sur-
vival in early breast cancer patients potentially leading
to a higher incidence of BMs [15-17]. Regardless of the
treatment used for BMs, breast cancer showed the high-
est 2-year survival rate (36%). The dramatic reduction of
survival at 2 years observed for NSCLC and melanoma
might be due to poor control of either cranial and extra-
cranial disease usually achieved in both malignancies,
thus reflecting the intrinsic radio-resistance of their
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Figure 1 Kaplan-Meier survival curves at 2 years according to primary tumor.
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BMs [18] and the low systemic efficacy of medical thera-
pies [19,20]. Similarly to breast cancer, a long time to
brain recurrence (42 months) was observed also for col-
orectal cancer. Nevertheless, only 18% of patients with
BMs from colorectal cancer survived at 1 year (in con-
trast with a 1-year survival of 58% for breast cancer
patients with BMs), indicating that in colorectal cancer
brain spread probably represents a final event in the
course of the disease.
In our series of patients, WBRT was the most used
up-front therapy for BMs (about 50% of patients) fol-
lowed by chemotherapy which was delivered in
approximately one fourth of cases. The reason why
many patients received chemotherapy as up-front
treatment for BMs despite the fact that only 41% of
patients suffered from multiple (> 3) brain lesions, can
be explained by several reasons. Firstly, nearly all
patients of our series had active systemic disease at the
time of diagnosis of brain metastases. Secondly, about
half of patients had no neurological symptoms, which
might have favored physicians’ choice of using che-
motherapy as up-front treatment for BMs along with
the fact that an oncology unit was available in each
institution. Finally, the presence of uncontrolled extra-
cranial disease might have played an important role in
selecting chemotherapy as first treatment option for
BMs, but the information about control rate on extra-
cranial sites could be retrieved only partially in our
patients, thus it was not considered for analysis. At the
present, no prospective comparison has ever been
made between chemotherapy and WBRT as upfront
treatment for brain metastases. Interestingly, a recent
survey suggests that in patients with asymptomatic
BMs from NSCLC, platinum-based chemotherapy pro-
vides equal benefit to WBRT as treatment of first
choice [21]. In our study the multivariate analysis
showed no prognostic difference between chemother-
apy and WBRT as up-front treatment for BMs, and
noteworthy this finding was independent from neuro-
logic status at diagnosis of brain metastases.
Table 4 Time to brain progression (TTBP) and overall survival (OS) according to the type of treatment for brain
metastases
Surgery-SRS 88 pts WBRT 136 pts Chemotherapy 66 pts
BPFa survival at 1 year 80 % 76 % 62 %
BPF survival at 2 years 71 % 53.5 % 34 %
median TTBP 27 months 25 months 14 months
(C.I. 95%:16-21) (C.I. 95%:20-30) (C.I. 95%:11-17)
1 year OS 74.9 % 47.3 % 33.6 %
2 years OS 42.1 % 23 % 11.5 %
median OS 18 months 10 months 8 months
(C.I. 95%:26-28) (C.I. 95%:7-14) (C.I. 95%:7-10)
aBrain Progression Free Survival.
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Figure 2 Kaplan-Meier survival curves at 2 years according to type of treatment for BMs.
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Of note, the multivariate analysis identified local
approaches (surgery and SRS) as independent prognostic
factors for survival. In this survey, we observed that a
local approach was delivered as up-front treatment in
approximately 30% of patients, despite the fact that some
data suggest that local treatment could be beneficial for
many patients with ≤ 3 brain metastases (59% of patients
from our series). To this regard, historical data indicate
that surgery might significantly prolong survival of
patients with single BMs [22,23], whereas more recently
it has been demonstrated that SRS alone might provide
equal results in terms of survival and neurocognitive
functioning to SRS plus WBRT in patients with ≤ 4 brain
lesions [24]. The discrepancy we found between the
number of patients with ≤ 3 brain metastases and those
who received a local approach, can be explained at least
in part by the fact that neurosurgery and SRS were avail-
able only in one centre. In fact, when patients with ≤ 3
BMs were analyzed on the basis of the resources available
at each center, a higher percentage of patients referring
to a comprehensive cancer center was preferentially trea-
ted with either surgery or SRS (group A) compared to
that treated in cancer institutions with no local treat-
ments (group B). Surprisingly, time to brain progression
for patients treated locally in each group versus those
receiving regional/systemic treatments did not differ sig-
nificantly. In our opinion, this finding can be ascribed to
the heterogeneous characteristics of our patients, which
reflects the scenario of clinical practice, where the choice
of front-line strategies for BMs are influenced not only
by the experience of each single physician, but also by
the availability of resources.
Conclusions
Cancer patients with BMs who are deemed eligible for a
local approach (SRS, surgery) on the basis of their clini-
cal characteristics might obtain improved survival from
such treatment. Neverthless, in order to optimize the
treatment of BMs, it becomes of crucial importance, to
carefully select patients who should be offered local
treatments for BMs.
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